[ad_1] Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images Most women should get screened for breast cancer every other year starting at age 40, a decade earlier than previously recommended, according to draft guidelines issued Tuesday by a government-backed panel…
[ad_1] A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Patrick Van Katwijk | Getty Images Shares of Novavax jumped more than 50% on Tuesday after the company unveiled promising new vaccine data and…
[ad_1] Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson consumer-health business, speaks during an interview with CNBC during his company’s IPO at the New York Stock Exchange (NYSE), May 4, 2023. Brendan McDermid | Reuters Kenvue CEO Thibaut Mongon is betting on brand and product innovation to drive growth at the newly spun-out…
[ad_1] Johnson & Johnson ‘s (JNJ) consumer-health unit Kenvue (KVUE) soared more than 22% on its first day of trading Thursday, bringing the Club holding one step closer to completing its business separation. The planned split, which is set for later this year, is in the best interest of shareholders of both the soon-to-be-solo Kenvue…
[ad_1] Shares of Johnson & Johnson‘s consumer-health spinoff Kenvue jumped 20% in afternoon trading Thursday after its market debut on the New York Stock Exchange, making it the biggest U.S. IPO in more than a year. The new company opened at $25.53 per share after originally pricing its initial public offering at $22 Wednesday night,…
[ad_1] Moderna’s sign is seen outside of their headquarters in Cambridge, MA on March 11, 2021. Boston Globe | Getty Images Moderna on Thursday blew past estimates for first-quarter earnings and revenue, posting a surprise quarterly profit, despite lower demand for Covid vaccines, its only marketable product. The biotech company generated first-quarter sales of $1.9…
[ad_1] Johnson & Johnson products on a shelf in a store in New York. Lucas Jackson | Reuters Johnson & Johnson’s consumer health business Kenvue priced its IPO at $22 per share Wednesday, toward the high end of its stated range, in an upsized deal that would bring in about $3.8 billion. At that IPO price, the new company…
[ad_1] A GSK lab in London. Oli Scarff | Getty Images The Food and Drug Administration on Wednesday approved an RSV vaccine produced by GlaxoSmithKline for use on adults ages 60 and older. The approval, the first ever globally by a regulatory body for an RSV vaccine, is a decisive victory for GSK in a…
[ad_1] Pfizer on Tuesday reported first-quarter revenue and adjusted earnings that topped Wall Street’s expectations, despite a decline in sales driven by the lower demand for the company’s Covid vaccine. The pharmaceutical giant’s stock edged higher in premarket trading Tuesday. Shares are down more than 23% for the year through Monday’s close, putting the company’s…
[ad_1] Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on October 4, 2021. NurPhoto | NurPhoto | Getty Images Merck on Thursday reported first-quarter revenue that fell 9% from the same period a year ago largely due to a steep drop in…
